Comparison · NCT01471522-sae
Invasive Strategy (INV) vs Conservative Strategy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Invasive Strategy (INV) vs Conservative Strategy: serious adverse events. Trial comparisons, record NCT01471522-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01471522-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.123 | 0.111 | 0.136 | wilson | |
| Risk in group 2 | 0.136 | 0.123 | 0.15 | wilson | |
| Risk difference, group 1 minus group 2 | -0.013 | -0.0313 | 0.00531 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.904 | 0.785 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.891 | 0.757 | 1.05 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Invasive Strategy (INV) than on Conservative Strategy | 77 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Invasive Strategy (INV) | Invasive Strategy (INV) | 318 | 2,588 | EG000 |
| Group 2 | Conservative Strategy | Conservative Strategy | 352 | 2,591 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 5 years
Source ClinicalTrials.gov
Trial
- Title
- International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
- NCT number
- NCT01471522
- Phases
- NA
- Conditions
- Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
- Interventions
- cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
- Lead sponsor
- NYU Langone Health
- Results first posted
- 2020-07-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01471522?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01471522-sae